These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 26826434)

  • 41. Systematic approach to understanding the pathogenesis of systemic sclerosis.
    Zuo X; Zhang L; Luo H; Li Y; Zhu H
    Clin Genet; 2017 Oct; 92(4):365-371. PubMed ID: 27918067
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Epigenetics, the holy grail in the pathogenesis of systemic sclerosis.
    Altorok N; Almeshal N; Wang Y; Kahaleh B
    Rheumatology (Oxford); 2015 Oct; 54(10):1759-70. PubMed ID: 24740406
    [TBL] [Abstract][Full Text] [Related]  

  • 43. T and NK Cell Phenotypic Abnormalities in Systemic Sclerosis: a Cohort Study and a Comprehensive Literature Review.
    Almeida I; Silva SV; Fonseca AR; Silva I; Vasconcelos C; Lima M
    Clin Rev Allergy Immunol; 2015 Dec; 49(3):347-69. PubMed ID: 26445774
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Emerging role of epigenetics in systemic sclerosis pathogenesis.
    Ciechomska M; van Laar JM; O'Reilly S
    Genes Immun; 2014 Oct; 15(7):433-9. PubMed ID: 25030429
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [B cell abnormalities and therapeutic strategies in systemic sclerosis].
    Yoshizaki A
    Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(3):197-206. PubMed ID: 27320935
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Role of B Cells in the Pathogenesis of Systemic Sclerosis.
    Sakkas LI; Bogdanos DP
    Isr Med Assoc J; 2016 Sep; 18(9):516-519. PubMed ID: 28471595
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The immunobiology of systemic sclerosis.
    Gu YS; Kong J; Cheema GS; Keen CL; Wick G; Gershwin ME
    Semin Arthritis Rheum; 2008 Oct; 38(2):132-60. PubMed ID: 18221988
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Potential use of TNF-α inhibitors in systemic sclerosis.
    Murdaca G; Spanò F; Contatore M; Guastalla A; Puppo F
    Immunotherapy; 2014; 6(3):283-9. PubMed ID: 24762073
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunogenetics of systemic sclerosis: Defining heritability, functional variants and shared-autoimmunity pathways.
    Bossini-Castillo L; López-Isac E; Martín J
    J Autoimmun; 2015 Nov; 64():53-65. PubMed ID: 26212856
    [TBL] [Abstract][Full Text] [Related]  

  • 50. T cell abnormalities in systemic sclerosis with a focus on Th17 cells.
    Brembilla NC; Chizzolini C
    Eur Cytokine Netw; 2012; 23(4):128-39. PubMed ID: 23360781
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of IL-13 in systemic sclerosis.
    Fuschiotti P
    Cytokine; 2011 Dec; 56(3):544-9. PubMed ID: 21920770
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A modified model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease.
    Ruzek MC; Jha S; Ledbetter S; Richards SM; Garman RD
    Arthritis Rheum; 2004 Apr; 50(4):1319-31. PubMed ID: 15077316
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New insights into CD4(+) T cell abnormalities in systemic sclerosis.
    Liu M; Wu W; Sun X; Yang J; Xu J; Fu W; Li M
    Cytokine Growth Factor Rev; 2016 Apr; 28():31-6. PubMed ID: 26724976
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Role of Epigenetic Modifications in Systemic Sclerosis: A Druggable Target.
    Henderson J; Distler J; O'Reilly S
    Trends Mol Med; 2019 May; 25(5):395-411. PubMed ID: 30858032
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Analysis of lymphocyte subpopulations in systemic sclerosis.
    Ercole LP; Malvezzi M; Boaretti AC; Utiyama SR; Rachid A
    J Investig Allergol Clin Immunol; 2003; 13(2):87-93. PubMed ID: 12968391
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association of a functional CD19 polymorphism with susceptibility to systemic sclerosis.
    Tsuchiya N; Kuroki K; Fujimoto M; Murakami Y; Tedder TF; Tokunaga K; Takehara K; Sato S
    Arthritis Rheum; 2004 Dec; 50(12):4002-7. PubMed ID: 15593213
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Pathogenesis of systemic scleroderma: immunological aspects].
    Mouthon L; García De La Peña-Lefebvre P; Chanseaud Y; Tamby MC; Boissier MC; Guillevin L
    Ann Med Interne (Paris); 2002 May; 153(3):167-78. PubMed ID: 12218899
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A polymorphism in the promoter region of the CD86 (B7.2) gene is associated with systemic sclerosis.
    Abdallah AM; Renzoni EA; Anevlavis S; Lagan AL; Munkonge FM; Fonseca C; Black CM; Briggs D; Wells AU; Marshall SE; McHugh N; du Bois RM; Welsh KI
    Int J Immunogenet; 2006 Jun; 33(3):155-61. PubMed ID: 16712644
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Immunopathological disturbances in systemic sclerosis].
    Gindzieńska-Sieśkiewicz E; Klimiuk PA; Kowal-Bielecka O; Sierakowski S
    Pol Merkur Lekarski; 2005 Dec; 19(114):800-3. PubMed ID: 16521427
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis.
    Fuschiotti P; Medsger TA; Morel PA
    Arthritis Rheum; 2009 Apr; 60(4):1119-28. PubMed ID: 19333920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.